HRS 2020: New Trial Data Support Medtronic’s Micra Pacemaker
Executive Summary
The Micra CED study showed a lower rate of complications with the Micra leadless pacemaker than transvenous single-chamber pacemakers.
You may also be interested in...
FDA Warns Of Severe Risks Associated With Medtronic Leadless Pacemakers
The US Food and Drug Administration has issued a warning to clinicians of the heightened risk for adverse events, including death, from potential cardiac perforation during implantation of Medtronic’s Micra Transcatheter Pacing System (TPS).
Cardiovascular Catch-Up: Abbott, Medtronic, Boston Scientific Stay Hot During Summer
June, July and August brought a number of important new approvals and trial announcements from the major cardiac device companies. Here are some of the highlights you might have missed during the summer.
Medtronic ‘Plays Offense’ Despite Pandemic Challenges, Q1 Results Provide Optimism
Medtronic’s revenue of $6.5bn in the first quarter of fiscal 2021 represents a 17% fall year-over-year, but it still beat analysts’ projections.